Abstract Library

#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors

Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Bianchi A, Iacovazzo D, Fusco A, Lugli F, Giampietro A,

Keywords: neuroendocrine tumor, somatostatin analogues, PRRT,

#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors

Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Korse C, Bonfrer J, van den Heuvel M, van Velthuysen M, Vincent A,

Keywords: Well- and moderately differentiated neuroendocrine tumors, proGastrin Releasing Peptide, chromogranin A, lung tumors,